DARTS Service for Drug Target Identification

Welcome to our specialized DARTS Service for Drug Target Identification. Drug Affinity Responsive Target Stability (DARTS) is a powerful, label-free target identification strategy that leverages the thermodynamic stabilization of proteins upon ligand binding. By measuring ligand-induced protease resistance across the native proteome, our platform helps researchers identify and validate the direct protein targets of small molecules without the need for chemical modification or probe synthesis.

Ideal for natural products, linker-intolerant small molecules, and orthogonal target confirmation after phenotypic screening, our DARTS workflow bridges the gap between a compelling biological phenotype and a validated mechanism of action.

Label-Free Target Identification: Discover targets using your unmodified, native compound.
No Probe Synthesis Required: Eliminate the time, cost, and SAR risks associated with designing chemical linkers.
Natural-Product Compatible: Perfectly suited for structurally complex or fragile secondary metabolites.
Supports Target Deconvolution: Seamlessly transition from phenotypic hits to prioritized candidate targets.

Assess DARTS Fit for Your Compound

What Is DARTS and Why Is It Useful for Label-Free Drug Target Identification?

Drug Affinity Responsive Target Stability (DARTS) is a biophysical technique used to identify drug-protein interactions based on the principle of ligand-induced protease protection. When a small molecule binds to its target protein, the resulting drug-protein complex generally adopts a more compact and thermodynamically stable conformation, or the ligand physically occludes protease cleavage sites via steric hindrance. This bound state "shields" the protein, making it significantly more resistant to digestion by broad-spectrum proteases (such as Pronase, Subtilisin, or Thermolysin) compared to the unbound, apo-state protein.

In a typical DARTS Service workflow, a native cell lysate is incubated with the unmodified drug, followed by controlled, limited proteolysis. Proteins that are stabilized by the drug remain intact, while unbound background proteins are digested into smaller fragments. The surviving (protected) proteins are then identified and quantified using either high-resolution LC-MS/MS (for unbiased target deconvolution) or SDS-PAGE/Western Blot (for targeted validation).

Because DARTS operates in complex, native lysates without requiring functionalized chemical probes, it represents a highly physiologically relevant method for label-free drug target identification.

Why Choose DARTS for Drug Target Identification and Natural Product Target Discovery?

Finding the direct molecular target of a promising small molecule is notoriously difficult, especially when the molecule's Structure-Activity Relationship (SAR) is completely unknown. DARTS directly solves several major bottlenecks in drug target discovery:

Zero Compound Modification Needed: Traditional affinity pull-down requires attaching a biotin or fluorophore linker to the drug. For many small molecules, adding a linker destroys or severely alters biological activity. DARTS uses the native, unaltered molecule, preserving its true binding characteristics and avoiding synthetic bottlenecks.
The Go-To Method for Natural Products: Natural products often possess complex, fragile stereochemistry that cannot be easily modified synthetically. DARTS has become the gold standard for natural product target identification because it bypasses the need for probe derivatization entirely.
Dual Utility (Discovery + Validation): DARTS is highly versatile. When coupled with global proteomics (LC-MS/MS), it acts as an unbiased discovery tool to deconvolve phenotypic targets. When coupled with Western blotting, it serves as a rapid, robust orthogonal validation assay to confirm suspected interactions in vitro.

Advantages of Our DARTS Analysis Service

At Creative Proteomics, we elevate DARTS from a simple gel-based assay into a highly reproducible, mass spectrometry-driven service.

Optimized Protease Kinetics

The success of DARTS depends entirely on the delicate balance of protease concentration and digestion time. We rigorously optimize the protease-to-protein ratio for your specific lysate to maximize the signal-to-noise ratio.

High-Resolution MS Integration

We couple DARTS with state-of-the-art Orbitrap LC-MS/MS platforms, allowing us to move beyond visualizing "a protected band on a gel" to delivering a statistically ranked list of prioritized protein targets.

Native-State Lysate Processing

Our customized, non-denaturing lysis buffers preserve the native folding and multi-protein complexes of your samples, ensuring that the protease protection you observe is biologically relevant.

Robust False-Positive Control

We incorporate mandatory vehicle controls, rigorous biological replicates, and advanced bioinformatics to statistically isolate true ligand-stabilized targets from random background fluctuations.

Technical Services

Service Scope Tech Comparison Workflow & QC Discovery vs Validation Deliverables & Results Case Study Sample Requirements FAQ Get a Custom Proposal

Scope of DARTS Services at Creative Proteomics

Target Deconvolution Post-Phenotypic Screening

Unbiased identification of the primary target driving a newly discovered biological effect.

Natural Product Target Identification

Uncovering the molecular mechanism of action for unmodified secondary metabolites and herbal extracts.

Orthogonal Target Validation

Providing independent, biophysical confirmation of targets previously identified by TPP, ABPP, or computational docking.

Protein-Protein Interaction (PPI) Modulator Profiling

Identifying targets of compounds designed to stabilize or disrupt native protein complexes, as ligand binding at the interface will alter protease accessibility.

When Should You Choose DARTS Instead of TPP, LiP-MS, or ABPP?

Selecting the right biophysical approach is the most critical decision in target discovery. Use the following selection matrix to understand how DARTS compares to other prominent target identification workflows.

Feature	DARTS	TPP	LiP-MS	ABPP
Probe / Linker Required?	No (Native drug)	No (Native drug)	No (Native drug)	Yes (Biotin/Alkyne)
Interaction Principle	Ligand-induced protease resistance (Thermodynamic/Steric)	Ligand-induced thermal stabilization (Delta Tm)	Peptide-level structural footprinting (Protease cleavage)	Covalent/Affinity probe enrichment
Best Suited For...	Natural products, linker-intolerant drugs, rapid orthogonal validation.	Live-cell target engagement, evaluating targets with measurable heat shifts.	Identifying the exact binding site/pocket on the target protein.	Covalent inhibitors, deep enrichment of low-abundance targets.
Primary Readout	SDS-PAGE (Validation) & LC-MS/MS (Discovery)	LC-MS/MS (Highly multiplexed)	LC-MS/MS (High-resolution)	LC-MS/MS & In-gel fluorescence

Method Selection Guide: When DARTS Is the Better First Choice

Choose DARTS over TPP if your suspected target protein is natively resistant to thermal denaturation (does not yield a clean melting curve in thermal shift assays), or if you need a simpler, rapid validation workflow via Western blot before committing to full proteome-wide TPP.
Choose DARTS over LiP-MS if your primary goal is to identify the overall target protein rather than mapping the specific peptide binding site. DARTS workflows are generally faster and slightly less bioinformatically intensive than full-scale LiP-MS for primary target identification.
Choose DARTS over ABPP if your compound loses biological activity when modified with a chemical linker, or if you lack the medicinal chemistry resources and time to synthesize and validate an active probe.

Standardized DARTS Workflow and Quality Control Strategy

To ensure reliable, publication-ready data, our DARTS Service follows a standardized, heavily controlled workflow.

Vertical workflow diagram for DARTS drug target identification.

Standardized DARTS workflow from native compound incubation to candidate target identification.

Native Compound Incubation

Cell or tissue lysates are incubated with the unmodified small molecule across a concentration gradient alongside a vehicle (DMSO) control to ensure binding is dose-dependent and saturable.

Protease Condition Optimization (QC Checkpoint)

We perform a pilot titration of the chosen protease (e.g., Pronase) to identify the optimal digestion window where background proteins are sufficiently degraded but the proteome is not completely obliterated.

Limited Proteolysis

The optimized protease concentration is applied equally to both the vehicle control and the compound-treated samples under strict temperature and time controls.

Differential Protection Readout

The digestion is halted, and the samples are prepared for readout. Ligand-bound proteins will show higher abundance (protection) in the treated samples compared to the vehicle control.

Protein Identification (LC-MS/MS or WB)

Protected fractions are analyzed via high-resolution Orbitrap mass spectrometry for global target discovery, or via Western blot for targeted validation.

Discovery vs Validation: How DARTS Proteomics Supports Candidate Target Identification

A common buyer confusion is whether DARTS is solely a validation tool. While DARTS was originally developed as a gel-based assay to confirm known interactions, Creative Proteomics heavily integrates it with quantitative LC-MS/MS to provide true target deconvolution.

Instead of visually inspecting a gel for a single darker band, our proteomics-enabled DARTS workflow digests the surviving protected proteins into peptides and quantifies them across all biological replicates.

By applying rigorous bioinformatics, we calculate the fold-change in protein abundance between the compound-treated and vehicle-treated samples. Proteins that are significantly more abundant in the treated group (surviving the protease) are prioritized. This shifts DARTS from a qualitative visual test into a statistically robust target prioritization model, capable of ranking primary targets and revealing secondary off-target interactions.

Project Deliverables and Representative Result Types

We provide decision-ready data packages that empower your next steps in lead optimization or IND filing. Our comprehensive reporting includes:

Methodology and Assay Report: Detailed protocols covering lysate preparation, protease optimization kinetics, and Orbitrap MS parameters.
Candidate Target Ranking List: A statistically filtered list of prioritized targets, annotated with fold-change, replicate consistency, and P-values.
Interpretive Summary: Expert pathway analysis and recommendations for orthogonal follow-up validation.

Gel panel demonstrating protected protein band in a DARTS assay.

Protected Band / Differential Proteolysis Readout

Representative DARTS readout showing ligand-induced protease protection (Western Blot validation).

Target ranking volcano plot for DARTS-based drug target identification.

Target Ranking Matrix or Candidate List

Ranked candidate target output from DARTS-based proteomics analysis highlighting statistically protected hits.

Orthogonal validation workflow combining phenotypic screening with DARTS.

Orthogonal Validation Schematic

DARTS utilized as an orthogonal biophysical validation method to confirm targets discovered through parallel multi-omics.

Pathway interpretation bubble chart for DARTS mass spectrometry data.

Pathway / MoA Interpretation Graphic

Pathway enrichment and network interpretation translating identified targets into a clear Mechanism of Action (MoA).

Case Study: Label-Free Target Identification by DARTS

Identifying the Direct Target of Resveratrol

Research Objective:

To identify the direct molecular target of the longevity-enhancing plant natural product resveratrol, utilizing the unmodified native compound without disrupting its biological activity.

How DARTS Was Used:

Because resveratrol lacks obvious functional groups for chemical tethering without altering its bioactivity, the researchers utilized DARTS.
Native resveratrol was incubated with human HeLa cell lysates. The mixture was then subjected to limited proteolysis using thermolysin or pronase.
The surviving, protease-resistant protein fractions were separated by SDS-PAGE, excised, and analyzed via high-resolution LC-MS/MS proteomics to identify proteins uniquely stabilized by resveratrol binding.

Key Findings from DARTS:

The DARTS assay successfully revealed the eukaryotic translation initiation machinery—specifically, the eukaryotic translation initiation factor 4A (eIF4A)—as a novel direct target of resveratrol.
The stabilization of eIF4A was dose-dependent and specific to the active compound, confirming a strong biophysical interaction.

Why DARTS Was Essential:

Resveratrol is a structurally sensitive native plant product. Traditional affinity-based target identification techniques would have required modifying the drug individually, which risks losing bioactivity.
DARTS allowed the identification of the target completely independent of synthetic chemistry constraints or prior mechanism-of-action assumptions.

Additional Techniques:

In vitro translation assays to confirm functional inhibition, and Western blotting for targeted orthogonal validation.

Reference:

Lomenick, B., Hao, R., Jonai, N., Chin, R. M., Aghajan, M., Warburton, S., ... & Huang, J. (2009). Target identification using drug affinity responsive target stability (DARTS). Proceedings of the National Academy of Sciences, 106(51), 21984-21989.

DARTS assay gel and proteomics data confirming resveratrol binding to eIF4A.

a. Protease protection profile of target protein eIF4A across increasing resveratrol concentrations.

b. LC-MS/MS identification and validation of the stabilized protein fraction.

Sample Requirements for DARTS Drug Target Identification Projects

To ensure the success of the limited proteolysis reaction, sample quality and native folding are paramount.

Sample Type	Minimum Requirement	Recommended Amount	Buffer / Preparation Notes	Suitable Readout
Cell Lysate / Cell Pellet	≥ 1-2 mg total protein	3-5 mg preferred	Native, non-denaturing buffer	SDS-PAGE or LC-MS/MS
Tissue Lysate	≥ 2 mg total protein	5 mg preferred	Homogenized in native buffer	SDS-PAGE or LC-MS/MS
Plant Tissues	≥ 1 g wet weight	2-5 g preferred	Requires specialized plant extraction protocols	SDS-PAGE or LC-MS/MS
Small Molecule	≥ 1-2 mg	5 mg (purity >95%)	DMSO stock or suitable solvent	All workflows
Recombinant Protein	≥ 100 µg	200 µg	Purified, native folding	Targeted Validation (WB)

Important Submission Notes:

Avoid strong denaturants (like urea or >0.1% SDS) during lysis, as the native protein fold must be intact for ligand binding and thermodynamic stabilization to occur.
Compound solvent compatibility should be confirmed before assay setup.
For global proteomics-based target identification, higher protein inputs are strongly preferred to ensure deep proteome coverage.

Frequently Asked Questions About DARTS Services

What types of compounds are best suited for DARTS?

DARTS is universally applicable to small molecules, but it is invaluable for natural products, non-covalent inhibitors, and structurally fragile compounds that cannot tolerate the addition of a chemical linker.

When should I choose DARTS instead of TPP?

While both are label-free, DARTS does not rely on heating the sample. Choose DARTS if your target proteins do not exhibit clear melting curves in thermal shift assays, or if you require a rapid, orthogonal validation method using standard Western blotting infrastructure.

Can DARTS identify targets for natural products?

Yes. Because DARTS uses the unmodified, native molecule, it is considered one of the premier methodologies for natural product target deconvolution.

Does DARTS require compound modification?

No. DARTS is completely label-free and relies solely on the natural binding affinity between your drug and its target.

Can DARTS be used for orthogonal validation?

Absolutely. DARTS is frequently utilized as a secondary biophysical validation step to confirm hits originally discovered via ABPP, TPP, phenotypic screening, or in silico docking.

What sample format is required?

We typically require native cell or tissue lysates (extracted without harsh denaturants) and the pure small molecule compound dissolved in a compatible solvent like DMSO.

Can DARTS be coupled to LC-MS/MS?

Yes. While often used with gels for targeted validation, Creative Proteomics couples DARTS with high-resolution Orbitrap mass spectrometry to perform unbiased, proteome-wide target discovery and candidate ranking.

What are the limitations of DARTS?

DARTS relies on the ligand inducing a sufficient conformational change or steric hindrance to protect against proteases. Very small ligands binding to massive, highly flexible proteins may occasionally fail to produce a strong enough protection signal to clearly separate from the background proteome. In such cases, orthogonal methods like LiP-MS or TPP are recommended.